Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

← catalyst calendar

NCT07470853 · readout ≤ 558 d

Sponsored by Whitehawk Therapeutics, Inc. (industry) · WHWK — their whole pipeline →. With Catalyst Pharmaceutical Research.

Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
265estimated
Sites
12
Country
United States

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2026-03-15actualWhen the study began enrolling
Primary completionFeb 2028estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completionFeb 2028estimatedThe whole study's end, after follow-up
First posted2026-03-13actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-08-18actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Conditions

  • PROC
  • Platinum Resistant Ovarian Cancer
  • Endometrial Cancer

Interventions

  • Drug: HWK-016, MUCIN-16-targeted ADC — also filed as HWK-016
  • Drug: Bevacizumab

Primary outcomes

what the primary-completion date above is the date OF
Determine Maximum Tolerated Dose (MTD)
measured From Cycle 1, Day 1 Until Cycle 1, Day 21 (21-day cycles)
Determine Maximum Administered Dose (MAD)
measured From Cycle 1, Day 1 to Cycle 1, Day 21 (21-day cycles) until the MTD is reached.
Determine Recommended Dose For Expansion (RDE)
measured From Cycle 1, Day 1 to Cycle 1, Day 21 (21-day cycle) until MTD is identified.

Permalink · WHWK's whole pipeline · Catalyst calendar · Every registered study · What changed